Posted on: 10 May 2019

(a) Cyclotek NSW Pty Ltd purchase of the Pettech Solutions Pty Ltd FDG business.  The Cyclotek Group now comprise five facilities stretched across the Australian eastern seaboard and New Zealand.

(b) Establishment of Applied Molecular Therapies Pty Ltd. This new entity will spearhead our launch into radionuclide therapies – Molecular Targeted Therapeutics

(c) Life Molecular Imaging approves the Technology Transfer of their Tau PET agent PI2620 for manufacture within Australia. Cyclotek has undertaken a GMP manufacture validation of this exciting  new tracer to enable it’s use in clinical trials within Australia and New Zealand.

(d) The 18F FP-CIT tracer for Parkinson Disease has undergone a technology transfer process. We now have a manufacturing methodology for the GE Fastlab synthesis unit and will progress to a GMP manufacturing validation in Q1-2020.

(e) The research team have worked solidly this year with RMIT and Cell Therapies on a complex radiolabelling  method incorporating a Superparamagnetic Iron Oxide Nanoparticle (SPION) with Cu64 and then loading onto CAR-T cells for a first into human trial.

[contact-form-7 id=”714″ title=”Update Form”]